Please login to the form below

Not currently logged in
Email:
Password:

Immuno-oncology's evolution: impacts for pharma market researchers
Immuno-oncology therapies that harness the body’s own defences to fight tumours are widely acknowledged as the new frontier in cancer treatment, but until recently only a few products had reached the market for a limited number of indications.

Over the past 12 months several new products have been approved for a wider range of tumour types and with pipelines boasting numerous other products in the area, competition looks set to hot up.

On November 17 Research Partnership, in association with PMGroup, will host a free webinar which will explore the key features of the immuno-oncology market and the critical success factors for remaining competitive.

Key areas that will be discussed include: 

Setting the context
The current situation in immuno-oncology and challenges and opportunities for new targeted therapies entering the market.

Portfolio Panning
Understanding where to invest in the early stages of new product development in order to achieve your objectives.

Marketing and communications
Considerations for the positioning and marketing communications strategy with regards to the evolution of each indication. How this will impact your market research needs.

Biomarker strategies
The impact of biomarker availability on patient selection and sequencing. How to ensure your biomarker strategies are optimised for your brand.

If you have any further comments or questions regarding today’s webinar or would like to know more about our experience in immuno-oncology research, please visit www.researchpartnership.com

 

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics